Oral VEGFR2 Inhibitor Rivoceranib for Recurrent or Metastatic Adenoid Cystic Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
A Phase 2 Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
Clin. Cancer Res 2023 Aug 29;[EPub Ahead of Print], GJ Hanna, MJ Ahn, J Muzaffar, B Keam, DW Bowles, DJ Wong, AL Ho, SB Kim, F Worden, T Yun, X Meng, JM Van Tornout, MG Conlan, H KangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.